Neurochem to begin Fibrillex Phase II/III

Neurochem (TSE:NRM) said it will begin a 150-patient international Phase II/III study in the U.S. and U.K. of its Fibrillex oral small molecule inhibitor of amyloid fiber formation to treat secondary ...